Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab in FH-deficient Renal Cell Carcinoma
NCT04146831Phase 2Unknown
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2020
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in Fumarate Hydratase-Deficient Renal Cell Carcinoma, sponsored by West China Hospital of Sichuan University. Primary endpoint: 6-month Progression-Free Survival Rate at 24 months. Status: unknown.
02
Drugs
sintilimab
03
Conditions
Fumarate Hydratase-Deficient Renal Cell Carcinoma
Beyond the preview
Go deeper on NCT04146831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04146831.